Amgen Release: Investigational Therapy Denosumab Increased Bone Mineral Density With Twice-Yearly Dosing

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 22, 2006--Amgen (NASDAQ: AMGN), the world's largest biotechnology company, announced today the publication of Phase 2 data demonstrating twice-yearly injections of denosumab (previously referred to as AMG 162), a RANK Ligand inhibitor, significantly increased bone mineral density (BMD) in the total hip, lumbar spine, distal 1/3 radius and total body compared to placebo. The results of this one-year study appeared in the Feb. 23, 2006 issue of the New England Journal of Medicine. Data results also included an open-label FOSAMAX(R) (alendronate)(a) arm of the same clinical trial.

Back to news